Saban D R, Chauhan S K, Zhang X, El Annan J, Jin Y, Dana R
Schepens Eye Research Institute, Boston, MA, USA.
Am J Transplant. 2009 Mar;9(3):473-82. doi: 10.1111/j.1600-6143.2008.02535.x.
Certain components of a graft that provoke alloimmunity may not be vital for graft function or critical as targets of rejection. Corneal transplantation is an example of this, because graft epithelium plays a role in allosensitization, whereas corneal graft endothelium-which shares the same alloantigens-is the critical target in allorejection. In this study, we found that exploiting this biology by replacing donor epithelium of an allograft with an allodisparate third-party epithelium yields a marked enhancement in transplant survival. Such 'chimeric' allografts consisted of a C3H/He (H-2(k)) corneal epithelium over a C57BL/6 (H-2(b)) epithelial-denuded cornea (or v.v.) and orthotopically placed on BALB/c (H-2(d)) hosts. Conventional corneal allografts (C3H/He or C57BL/6) or isografts (BALB/c) were also transplanted on BALB/c hosts. Alloreactive T-cell frequencies (CD4(+) interferon [IFN]-gamma(+)) primed to the graft endothelium were strongly diminished in chimeric hosts relative to conventionally allografted hosts. This was corroborated by a decreased T-cell infiltration (p = 0.03) and a marked enhancement of allograft survival (p = 0.001). Our results represent the first successful demonstration of chimeric tissue, epithelial-denuded allograft plus third-party allodisparate epithelium, in the promotion of allograft survival. Moreover, chimeric grafting can be readily performed clinically, whereby corneal allograft rejection remains a significant problem particularly in inflamed graft beds.
移植物中某些引发同种异体免疫的成分可能对移植物功能并非至关重要,也不是排斥反应的关键靶点。角膜移植就是一个例子,因为移植上皮在同种致敏中起作用,而具有相同同种抗原的角膜移植内皮是同种异体排斥反应中的关键靶点。在本研究中,我们发现利用这一生物学特性,用异体不同的第三方上皮替代同种异体移植物的供体上皮,可显著提高移植存活率。这种“嵌合”同种异体移植物由C3H/He(H-2(k))角膜上皮覆盖在C57BL/6(H-2(b))上皮剥脱的角膜上(或反之亦然),并原位移植到BALB/c(H-2(d))宿主上。传统的角膜同种异体移植物(C3H/He或C57BL/6)或同基因移植物(BALB/c)也移植到BALB/c宿主上。相对于传统同种异体移植宿主,嵌合宿主中针对移植物内皮引发的同种反应性T细胞频率(CD4(+)干扰素[IFN]-γ(+))显著降低。这通过T细胞浸润减少(p = 0.03)和同种异体移植物存活率显著提高(p = 0.001)得到证实。我们的结果首次成功证明了嵌合组织,即上皮剥脱的同种异体移植物加第三方异体不同上皮,可促进同种异体移植物存活。此外,嵌合移植在临床上很容易进行,而角膜同种异体移植排斥仍然是一个重大问题,尤其是在炎症性移植床中。